Xtant Medical Holdings (FRA:XMS) ROCE % : -20.74% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Xtant Medical Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xtant Medical Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -20.74%.

Xtant Medical Holdings ROCE % Historical Data

The historical data trend for Xtant Medical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings ROCE % Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-6.98

-2.84

-13.22

-15.65

3.28

Xtant Medical Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-13.03	-11.74	52.32	-16.47	-20.74

Xtant Medical Holdings ROCE % Calculation

Xtant Medical Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1.743	/	( ( (56.856 - 14.366)	+	(84.925 - 21.082) )	/ 2 )
	=	1.743	/	( (42.49	+	63.843)	/ 2 )
	=	1.743	/	53.1665
	=	3.28 %

Xtant Medical Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-12.868	/	( ( (84.925 - 21.082)	+	(86.417 - 26.167) )	/ 2 )
	=	-12.868	/	( ( 63.843	+	60.25 )	/ 2 )
	=	-12.868	/	62.0465
	=	-20.74 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Xtant Medical Holdings (FRA:XMS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xtant Medical Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (FRA:XMS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (FRA:XMS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XTNT:USA

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Xtant Medical Holdings (FRA:XMS) Headlines

No Headlines